vTv Therapeutics (VTVT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$98.5 million.
- vTv Therapeutics' Enterprise Value fell 15400.72% to -$98.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.5 million, marking a year-over-year decrease of 15400.72%. This contributed to the annual value of -$34.7 million for FY2024, which is 92748.52% down from last year.
- Per vTv Therapeutics' latest filing, its Enterprise Value stood at -$98.5 million for Q3 2025, which was down 15400.72% from -$26.3 million recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' Enterprise Value registered a high of $54.1 million during Q1 2021, and its lowest value of -$98.5 million during Q3 2025.
- Moreover, its 5-year median value for Enterprise Value was $785000.0 (2023), whereas its average is -$8.3 million.
- In the last 5 years, vTv Therapeutics' Enterprise Value skyrocketed by 40275.5% in 2023 and then tumbled by 610942.68% in 2024.
- vTv Therapeutics' Enterprise Value (Quarter) stood at $11.4 million in 2021, then plummeted by 61.23% to $4.4 million in 2022, then plummeted by 176.16% to -$3.4 million in 2023, then tumbled by 927.49% to -$34.7 million in 2024, then tumbled by 183.64% to -$98.5 million in 2025.
- Its Enterprise Value was -$98.5 million in Q3 2025, compared to -$26.3 million in Q2 2025 and -$30.1 million in Q1 2025.